IP Library › Granted Patent US 12,268,651
Granted Patent B2
US 12,268,651 · App. 17/057,171 · Granted Apr 8, 2025

Soft contact lens

Inventor: Alessandro Filippo (Varmo, IT)
Assignee: Cataltheia Group, Inc.
A61H35/02A61F9/0008G02C7/047G02C7/049G02C2202/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,651
App. No.
17/057,171
Granted
Apr 8, 2025
Kind
B2
Abstract

A soft contact lens comprises a solid component, based on a polymer and a liquid component which is distributed in a substantially uniform manner in the solid component. The liquid component comprises an effective quantity of a compound selected from the group formed by tyrosine, derivatives of tyrosine, precursors of tyrosine and dopamine which is capable of preventing or at least limiting the progression of myopia of the eye.

Claims (17)

1. A soft contact lens ( 4 ) comprising a solid component, based on a polymer, which is provided for conferring shape and structure on the contact lens and a liquid component which is distributed in the solid component, the liquid component comprises tyrosine at a concentration between 1 and 200 mg/l.

2. The contact lens according to claim 1 , wherein the concentration of tyrosine in the liquid component is between 10 and 100 mg/l.

3. The contact lens according to claim 1 , wherein the liquid component comprises L-tyrosine.

4. The contact lens according to claim 1 , wherein the liquid component further comprises an antioxidant compound.

5. The contact lens according to claim 4 , wherein the antioxidant compound comprises vitamin E or vitamin B2 or admixtures thereof.

6. The contact lens according to claim 5 , wherein the vitamin E, when present, has a concentration between 2 and 20 mg/l, and the vitamin B2, when present, has a concentration between 2 and 50 μg/l.

7. A packaging ( 1 ) comprising a soft contact lens ( 4 ) which is immersed in a preservation solution ( 5 ), wherein the contact lens is in accordance with claim 1 , comprising a solid component based on a polymer and a liquid component which is distributed in the solid component and in which there is dissolved tyrosine at a concentration between 1 and 200 mg/l, and the preservation solution ( 5 ) comprises tyrosine at a concentration which is at least equal to the concentration present in the liquid component.

8. A process for producing a soft contact lens according to claim 1 , the process comprising:

providing a dry semi-finished product of the lens which is based on a polymer and which is configured to form a solid component of the soft contact lens,

hydrating the dry semi-finished product by means of immersion in an aqueous solution so as to bring a liquid component to the solid component and to thereby obtain the soft contact lens,

the aqueous solution comprises tyrosine at a concentration between 1 and 200 mg/l.

9. A process for producing a soft contact lens according to claim 1 , the process comprising:

providing a dry semi-finished product of the lens which is based on a polymer and which is configured to form a solid component of the soft contact lens,

hydrating the dry semi-finished product by means of immersion in an aqueous solution so as to bring a liquid component to the solid component and to thereby obtain the soft contact lens,

packaging the soft contact lens inside a container in which it is immersed in a preservation solution,

subjecting the packaging containing the soft contact lens to a sterilizing processing operation in an autoclave,

the preservation solution comprises tyrosine at a concentration between 1 and 200 mg/l.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: BF RESEARCH S.R.L.
To: CATALTHEIA GROUP, INC.
Reel/Frame 070390/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2020
From: FILIPPO, ALESSANDRO
To: BF RESEARCH S.R.L.
Reel/Frame 054596/0001 →
Priority Claims (1)
IT 102018000005599 · May 22, 2018 · national
Continuity (1)
Related Publication 20210294125A1 · Sep 23, 2021
References Cited (51)
US 3710796A · Neefe · 1973 [cited by examiner]
US 4466705A · Michelson · 1984 [cited by applicant]
US 4668506A · Bawa · 1987 [cited by examiner]
US 5187207A · Gallas · 1993 [cited by applicant]
US 5284843A · Stone et al. · 1994 [cited by applicant]
US 7132567B2 · Alberte · 2006 [cited by examiner]
US 20060271027A1 · Silvestrini · 2006 [cited by examiner]
US 20120088861A1 · Huang · 2012 [cited by examiner]
US 20140036225A1 · Chehab et al. · 2014 [cited by applicant]
US 20160018671A1 · Waite et al. · 2016 [cited by applicant]
US 20160338947A1 · Leahy et al. · 2016 [cited by applicant]
US 20170326088A1 · Vidyasagar · 2017 [cited by examiner]
US 20170368061A1 · Nguyen · 2017 [cited by examiner]
US 20180094137A1 · MacKay et al. · 2018 [cited by applicant]
CN 103576337B · 2018 [cited by applicant]
CN 105434439B · 2018 [cited by applicant]
EP 0834308A1 · 1998 [cited by applicant]
EP 2693259A1 · 2014 [cited by examiner]
JP S61077822A · 1986 [cited by applicant]
JP H09503752A · 1997 [cited by applicant]
JP 2003055225A · 2003 [cited by applicant]
JP 2004203867A · 2004 [cited by applicant]
JP 2005084558A · 2005 [cited by applicant]
JP 2005154437A · 2005 [cited by applicant]
JP 2010204579A · 2010 [cited by applicant]
JP 2013190789A · 2013 [cited by applicant]
JP 2014032404A · 2014 [cited by applicant]
JP 2015509205A · 2015 [cited by applicant]
JP 2018532835A · 2018 [cited by applicant]
WO 8901639A1 · 1989 [cited by applicant]
WO WO2010039939A1 · 2010 [cited by examiner]
WO 2016187426A1 · 2016 [cited by applicant]
WO 2017055536A1 · 2017 [cited by applicant]
WO 2017140846A1 · 2017 [cited by applicant]
WO 2017177262A1 · 2017 [cited by applicant]
International Preliminary Report on Patentability issued Dec. 3, 2020, by the International Bureau of WIPO for PCT/IB2019/054016. [cited by applicant]
Morgan IG et al.; The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res 2018; 62:134-49; (2017). [cited by applicant]
Yanxian C et al.; Best practice in myopia control: insights and innovations for myopia prevention and control—a round table discussion. Br J Ophthalmol 2024; 108(7) 913-4; (May 10, 2024). [cited by applicant]
Feldkaemper M and Schaeffel F.; An updated view on the role of dopamine in myopia Experimental Eye Research 2013; 114:106-19; (Feb. 19, 2013). [cited by applicant]
Thomson K et al.; Effectiveness and safety of topical levodopa in a chick model of myopia. Scientific Reports 2019; 9:18345. doi.org/10.1038/s41598-019-54789-5; (Dec. 4, 2019). [cited by applicant]
Torii H et al.; Violet light exposure can be a preventive strategy against myopia progression. EBioMedicine 2017; 15:210-9; (Dec. 16, 2016). [cited by applicant]
DelMonte DW and Kim T.; Anatomy and physiology of the cornea. J Cataract Refract Surg 2011; 37:588-98; (Oct. 29, 2010). [cited by applicant]
Bodor N, Buchwald P.; Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 2005;7(4) Article 79:E820; (Dec. 7, 2005). [cited by applicant]
Santana CP et al.; Corneal Permeability and Uptake of Twenty-Five Drugs: Species Comparison and Quantitative Structure-Permeability Relationships. Pharmaceutics 2023, 15, 1646, at 2; (Jun. 2, 2023). [cited by applicant]
Weng Y et al.; Nanotechnology-based strategies for treatment of ocular disease, Acta Pharmaceutica Sinica 2017; B281, at 281; (Jul. 6, 2016). [cited by applicant]
Vinciguerra P et al.; Use of amino acids in refractive surgery. Journal of Refractive Surgery 2002; 18:S374-377; (Dec. 14, 2001). [cited by applicant]
Marx S et al.; Objective analysis of pre-lens tear film stability of daily disposable contact lenses using ring mire projection. Clinical Optometry 2020; 12:203-11; (Dec. 2020). [cited by applicant]
Wilson SL et al.; Control of scar tissue formation in the cornea: strategies in clinical and corneal tissue engineering. J Funct Biomater 2012; 642:648; (Sep. 18, 2012). [cited by applicant]
Rusciano D et al.; Free amino acids: an innovative treatment for ocular surface disease. European Journal of Pharmacology 2016; 787: 9-19; (Apr. 14, 2016). [cited by applicant]
Hirshfield, GS; Why can't I use my skin ointment on my eyes?, American Academy of Ophthalmology, available at https://www.aao.org/eye-health/ask-ophthalmologist-q/why-can-t-i-use-my-skin-ointment-on-my-eyes#:˜:text=Answ… [cited by applicant]
Zhou X et al.; Dopamine signaling and myopia development: what are the key challenges.Research 2017; 61:60-71; (Jun. 7, 2017). [cited by applicant]